Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies

BY Benzinga
— 9:21 AM ET 04/11/2022

Syros Pharmaceuticals Inc NASDAQ:SYRS announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity in models of breast, lung, and ovarian cancer, including in a PARP inhibitor-resistant model. 

  • The data support the advancement of a development candidate from Syros' CDK12 inhibitor program towards clinical development. 
  • As a single agent in cancer cell models, the CDK12 inhibitor induced DNA damage, cell cycle dysregulation, and genomic instability leading to growth inhibition and apoptosis. 
  • Additionally, as a single agent in in vivo cancer models, the Company's CDK12 inhibitor demonstrated tumor regressions in small cell lung cancer and breast cancer models at well-tolerated doses.
  • Related: Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings.
  • In combination in vitro, the CDK12 inhibitor exhibited synergistic or additive antiproliferative effects with lurbinectedin and olaparib, with increases in DNA damage and impaired DNA damage repair. 
  • Lurbinectedin is marketed by Jazz Pharmaceutical Inc NASDAQ:JAZZ as Zepzelca and AstraZeneca Plc NASDAQ:AZN - Merck & Co Inc's NYSE:MRK market olaparib under Lynparza name.
  • Price Action: SYRS shares are down 7.83% at $1.06 during the premarket session on the last check Monday.

More SYRS News

  • Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022
    Business Wire - 1:00 PM ET 04/08/2022
  • Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed
    Benzinga - 11:05 AM ET 03/16/2022
  • Recap: Syros Pharmaceuticals Q4 Earnings
    Benzinga - 7:51 AM ET 03/15/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close